Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Drugs and Chemicals›Penicillin G
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

Penicillin G

Drugs and Chemicals · NLM MeSH · updated 2026-10-31 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections.

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (908 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on gamma-aminobutyric acid mediated synaptic transmission.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Benzylpenicillin; Penicillin G Sodium; Sodium Benzylpenicillin; Sodium Penicillin; Pfizerpen; Ursopen; Penicillin G Potassium; Benzylpenicillin Potassium.

Where it fits in the MeSH classification

Broader topics
Penicillins
Narrower topics
Ampicillin; Carbenicillin; Penicillin G Benzathine; Penicillin G Procaine; Sulbenicillin

Related concepts

  • Gamma-Aminobutyric Acid

Research landscape

PubMed indexes 43,785 records tagged with the MeSH heading “Penicillin G” (counts retrieved 2026-10-31). 4,857 of them (11.1%) were published from 2020 onward, and the busiest period so far is through 1999 with 25,628 records.

Reviews account for 2,316 records (5.3%) and meta-analyses for 300. Randomized controlled trials number 3,896 (8.9%) as a share of all records on the topic. Randomized trials make up a comparatively large share of this literature, which means many treatment questions have been tested directly.

PubMed records by publication periodthrough 1999: 25,628 records; 2000-2009: 6,224 records; 2010-2019: 7,076 records; 2020 onward: 4,857 records25,628through 19996,2242000-20097,0762010-20194,8572020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 199925,628
2000-20096,224
2010-20197,076
2020 onward4,857
Share of records by publication typeReviews: 5.3 percent; Meta-analyses: 0.7 percent; Randomized controlled trials: 8.9 percentReviews5.3% (2,316)Meta-analyses0.7% (300)Randomized controlled trials8.9% (3,896)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 43,785 PubMed records
TypeRecordsShare
Reviews2,3165.3%
Meta-analyses3000.7%
Randomized controlled trials3,8968.9%

Method: PubMed query "Penicillin G"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.

Reading the evidence in drugs and chemicals

Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Effects of different amoxicillin treatment durations on microbiome diversity and composition in the gut
Lekang K, Shekhar S, Berild D, Petersen FC, Winther-Larsen HC
2022Research article
Design not recorded in structured metadata
29cc by
PMID 36301847 · DOI · PMC9612567
Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam
Tran TT, Nguyen AT, Quach DT, Pham DT, Cao NM, Nguyen UT, et al.
2022Research article
Design not recorded in structured metadata
25cc by
PMID 35114945 · DOI · PMC8812189
Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance
Gross R, Yelin I, Lázár V, Datta MS, Kishony R
2024Research article
Design not recorded in structured metadata
24cc by
PMID 38918379 · DOI · PMC11199616
Evaluating the duration of post-discontinuation therapeutic ampicillin exposures in preterm infants
Boutzoukas AE, Le J, Kilpatrick R, Smith MJ, Laughon M, Gonzalez D, et al.
2026Research article
Design not recorded in structured metadata
2cc by
PMID 41826670 · DOI · PMC13290478

Effects of different amoxicillin treatment durations on microbiome diversity and composition in the gut [1]

Research article Lekang K, Shekhar S, Berild D, Petersen FC, Winther-Larsen HC · · 2022 · cited 29 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Antibiotics seize an effect on bacterial composition and diversity and have been demonstrated to induce disruptions on gut microbiomes.
Closing excerpt
This may strengthen the argument for shorter antibiotic treatment regimens to both limit the emergence of antibiotic resistance and risk of gut microbiome disturbance.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (343 words)

Antibiotics seize an effect on bacterial composition and diversity and have been demonstrated to induce disruptions on gut microbiomes. This may have implications for human health and wellbeing, and an increasing number of studies suggest a link between the gut microbiome and several diseases. Hence, reducing antibiotic treatments may be beneficial for human health status. Further, antimicrobial resistance (AMR) is an increasing global problem that can be counteracted by limiting the usage of antibiotics. Longer antibiotic treatments have been demonstrated to increase the development of AMR. Therefore, shortening of antibiotic treatment durations, provided it is safe for patients, may be one measure to reduce AMR. In this study, the objective was to investigate effects of standard and reduced antibiotic treatment lengths on gut microbiomes using a murine model. Changes in the murine gut microbiome was assessed after using three different treatment durations of amoxicillin (3, 7 or 14 days) as well as a control group not receiving amoxicillin. Fecal samples were collected before and during the whole experiment, until three weeks past end of treatment. These were further subject for 16S rRNA Illumina MiSeq sequencing. Our results demonstrated significant changes in bacterial diversity, richness and evenness during amoxicillin treatment, followed by a reversion in terms of alpha-diversity and abundance of major phyla, after end of treatment. However, a longer restitution time was indicated for mice receiving amoxicillin for 14 days, and phylum Patescibacteria did not fully recover. In addition, an effect on the composition of Firmicutes was indicated to last for at least three weeks in mice treated with amoxicillin for 14 days. Despite an apparently reversion to a close to original state in overall bacterial diversity and richness, the results suggested more durable changes in lower taxonomical levels. We detected several families, genera and ASVs with significantly altered abundance three weeks after exposure to amoxicillin, as well as bacterial taxa that appeared significantly affected by amoxicillin treatment length. This may strengthen the argument for shorter antibiotic treatment regimens to both limit the emergence of antibiotic resistance and risk of gut microbiome disturbance.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36301847 · DOI · PMC9612567

Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam [2]

Research article Tran TT, Nguyen AT, Quach DT, Pham DT, Cao NM, Nguyen UT, et al. · · 2022 · cited 25 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundAmoxicillin-resistant Helicobacter pylori (H.
Closing excerpt
Additional studies are necessary to identify the mechanisms contributing to this resistance in Vietnam.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (322 words)

BackgroundAmoxicillin-resistant Helicobacter pylori (H. pylori) strains seem to have increased over time in Vietnam. This threatens the effectiveness of H. pylori eradication therapies with this antibiotic. This study aimed to investigate the prevalence of primary resistance of H. pylori to amoxicillin and to assess its association with pbp1A point mutations in Vietnamese patients.Materials and methodsNaive patients who presented with dyspepsia undergoing upper gastrointestinal endoscopy were recruited. Rapid urease tests and PCR assays were used to diagnose H. pylori infection. Amoxicillin susceptibility was examined by E-tests. Molecular detection of the mutant pbp1A gene conferring amoxicillin resistance was carried out by real-time PCR followed by direct sequencing of the PCR products. Phylogenetic analyses were performed using the Tamura-Nei genetic distance model and the neighbor-joining tree building method.ResultsThere were 308 patients (46.1% men and 53.9% women, p = 0.190) with H. pylori infection. The mean age of the patients was 40.5 ± 11.4 years, ranging from 18 to 74 years old. The E-test was used to determine the susceptibility to amoxicillin (minimum inhibitory concentration (MIC) ≤ 0.125 μg/ml) in 101 isolates, among which the rate of primarily resistant strains to amoxicillin was 25.7%. Then, 270 sequences of pbp1A gene fragments were analysed. There were 77 amino acid substitution positions investigated, spanning amino acids 310-596, with the proportion varying from 0.4 to 100%. Seven amino acid changes were significantly different between amoxicillin-sensitive (AmoxS) and amoxicillin-resistant (AmoxR) samples, including Phe366 to Leu (p 414 to Arg (p 464-465 (p = 0.009), Val469 to Met (p = 0.021), Phe473 to Val (p 479 to Glu (p = 0.044), and Ser/Ala/Gly595-596 (p = 0.001). Phylogenetic analyses suggested that other molecular mechanisms might contribute to amoxicillin resistance in H. pylori in addition to the alterations in PBP1A.ConclusionsWe reported the emergence of amoxicillin-resistant Helicobacter pylori strains in Vietnam and new mutations statistically associated with this antimicrobial resistance. Additional studies are necessary to identify the mechanisms contributing to this resistance in Vietnam.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 35114945 · DOI · PMC8812189

Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance [3]

Research article Gross R, Yelin I, Lázár V, Datta MS, Kishony R · · 2024 · cited 24 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
The incidence of beta-lactam resistance among clinical isolates is a major health concern.
Closing excerpt
Our results reveal that combinations of distinct genetic mutations, accessible at large population sizes, can drive high-level resistance to ampicillin even independently of beta-lactamases.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (163 words)

The incidence of beta-lactam resistance among clinical isolates is a major health concern. A key method to study the emergence of antibiotic resistance is adaptive laboratory evolution. However, in the case of the beta-lactam ampicillin, bacteria evolved in laboratory settings do not recapitulate clinical-like resistance levels, hindering efforts to identify major evolutionary paths and their dependency on genetic background. Here, we used the Microbial Evolution and Growth Arena (MEGA) plate to select ampicillin-resistant Escherichia coli mutants with varying degrees of resistance. Whole-genome sequencing of resistant isolates revealed that ampicillin resistance was acquired via a combination of single-point mutations and amplification of the gene encoding beta-lactamase AmpC. However, blocking AmpC-mediated resistance revealed latent adaptive pathways: strains deleted for ampC were able to adapt through combinations of changes in genes involved in multidrug resistance encoding efflux pumps, transcriptional regulators, and porins. Our results reveal that combinations of distinct genetic mutations, accessible at large population sizes, can drive high-level resistance to ampicillin even independently of beta-lactamases.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 38918379 · DOI · PMC11199616

Evaluating the duration of post-discontinuation therapeutic ampicillin exposures in preterm infants [4]

Research article Boutzoukas AE, Le J, Kilpatrick R, Smith MJ, Laughon M, Gonzalez D, et al. · · 2026 · cited 2 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
ObjectiveDetermine if preterm infants have prolonged therapeutic post-discontinuation antibiotic exposures (PDAE) following empiric ampicillin.
Closing excerpt
Shorter courses could be considered.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (80 words)

ObjectiveDetermine if preterm infants have prolonged therapeutic post-discontinuation antibiotic exposures (PDAE) following empiric ampicillin.Study designProspective study of 27 infants ≤7 days and ResultAt 24- and 36-h after ampicillin, the probability of exposures ≥1 μg/mL was 95% and 60%, respectively. PDAE (≥1 μg/mL) lasted a median 33 h (95% confidence interval: 15, 79), and varied with GA, from median 53 h (ConclusionMany preterm infants experience therapeutic exposures at least 24 h after the final ampicillin dose. Shorter courses could be considered.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41826670 · DOI · PMC13290478

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Drug-induced liver injury [5]
    Leise MD, Poterucha JJ, Talwalkar JA · Mayo Clin Proc · 2014 · cited 270 times (Europe PMC)
  • Research article Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis [6]
    Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ · Clin Infect Dis · 2013 · cited 206 times (Europe PMC)
  • Research article Treatment of syphilis: a systematic review [7]
    Clement ME, Okeke NL, Hicks CB · JAMA · 2014 · cited 188 times (Europe PMC)
  • Research article Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage [8]
    Huttner A, Bielicki J, Clements MN, Frimodt-Møller N, Muller AE, Paccaud JP, et al. · Clin Microbiol Infect · 2020 · cited 173 times (Europe PMC)
  • Research article A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection [9]
    Calvet X, Calvet X, García N, López T, Gisbert JP, Gené E, et al. · Aliment Pharmacol Ther · 2000 · cited 170 times (Europe PMC)
  • Research article Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail [10]
    Gisbert JP, Pajares JM · Aliment Pharmacol Ther · 2002 · cited 165 times (Europe PMC)

References

  1. Lekang K, Shekhar S, Berild D, Petersen FC, Winther-Larsen HC. Effects of different amoxicillin treatment durations on microbiome diversity and composition in the gut. . 2022. PMID 36301847 · DOI · PMC9612567
  2. Tran TT, Nguyen AT, Quach DT, Pham DT, Cao NM, Nguyen UT, et al.. Emergence of amoxicillin resistance and identification of novel mutations of the pbp1A gene in Helicobacter pylori in Vietnam. . 2022. PMID 35114945 · DOI · PMC8812189
  3. Gross R, Yelin I, Lázár V, Datta MS, Kishony R. Beta-lactamase dependent and independent evolutionary paths to high-level ampicillin resistance. . 2024. PMID 38918379 · DOI · PMC11199616
  4. Boutzoukas AE, Le J, Kilpatrick R, Smith MJ, Laughon M, Gonzalez D, et al.. Evaluating the duration of post-discontinuation therapeutic ampicillin exposures in preterm infants. . 2026. PMID 41826670 · DOI · PMC13290478
  5. Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. Mayo Clin Proc. 2014. PMID 24388027 · DOI
  6. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013. PMID 23074314 · DOI
  7. Clement ME, Okeke NL, Hicks CB. Treatment of syphilis: a systematic review. JAMA. 2014. PMID 25387188 · DOI · PMC6690208
  8. Huttner A, Bielicki J, Clements MN, Frimodt-Møller N, Muller AE, Paccaud JP, et al.. Oral amoxicillin and amoxicillin-clavulanic acid: properties, indications and usage. Clin Microbiol Infect. 2020. PMID 31811919 · DOI
  9. Calvet X, Calvet X, García N, López T, Gisbert JP, Gené E, et al.. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000. PMID 10792124 · DOI
  10. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther. 2002. PMID 12030945 · DOI

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-31.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • SulbactamDrugs and Chemicals
  • PenicillinsDrugs and Chemicals
  • MethicillinDrugs and Chemicals
  • TazobactamDrugs and Chemicals
  • CarbenicillinDrugs and Chemicals
  • PiperacillinDrugs and Chemicals

All 546 articles in Drugs and Chemicals →

At a glance

43,785
PubMed records on this heading
11%
published since 2020
2,316
review articles
3,896
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-31; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • SulbactamDrugs and Chemicals
  • PenicillinsDrugs and Chemicals
  • MethicillinDrugs and Chemicals
  • TazobactamDrugs and Chemicals
  • CarbenicillinDrugs and Chemicals

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support